咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Recombinant chimpanzee adenovi... 收藏

Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice

Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice

作     者:Mingqing Lu Kunpeng Liu Yun Peng Zhe Ding Yingwen Li Alexander Tendu Xue Hu Ge Gao Weiwei Guo Hang Liu Juhong Rao Jiaxuan Zhao Miaoyu Chen Zhiming Yuan Gary Wong Chao Shan Yanfeng Yao Jiaming Lan Mingqing Lu;Kunpeng Liu;Yun Peng;Zhe Ding;Yingwen Li;Alexander Tendu;Xue Hu;Ge Gao;Weiwei Guo;Hang Liu;Juhong Rao;Jiaxuan Zhao;Miaoyu Chen;Zhiming Yuan;Gary Wong;Chao Shan;Yanfeng Yao;Jiaming Lan

作者机构:CAS Key Laboratory of Molecular Virology&ImmunologyInstitut Pasteur of ShanghaiChinese Academy of SciencesShanghai200031China State Key Laboratory of VirologyChinese Academy of SciencesWuhan430071China University of Chinese Academy of SciencesBeijing100049China Center for Biosafety Mega-ScienceWuhan Institute of VirologyChinese Academy of SciencesWuhan430071China 

出 版 物:《Virologica Sinica》 (中国病毒学(英文版))

年 卷 期:2022年第37卷第4期

页      面:581-590页

核心收录:

学科分类:1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基  金:the National Natural Science Foundation of China(No.32070933 to J.M.Lan and Y.F.Yao) the Natural Science Foundation of Shanghai(No.20ZR1463900 to J.M.Lan) financially the STS regional key project(KFJ-STS-QYZD-2021-12-001 to Z.M.Yuan and C.Shan)from Chinese Academy of Sciences National Key R&D Program of China 2021YFE0201900 to C.Shan and 2021YFC0863300 to Z.M.Yuan and C.Shan the National Key R&D Program of China(No.2021YFC0863400) funding from Institut Pasteur,Fondation Merieux and the Chinese Academy of Sciences to G.W 

主  题:SARS-CoV-2 Vaccine Chimpanzee adenovirus vector Neutralizing antibodies Long-term protection 

摘      要:SARS-CoV-2 infection is a global public health *** are considered amongst the most important tools to control the SARS-CoV-2 *** expected,deaths from SARS-CoV-2 infection have dropped dramatically with widespread ***,there are concerns over the duration of vaccine-induced protection,as well as their effectiveness against emerging variants of ***,we constructed a recombinant chimpanzee adenovirus vectored vaccine expressing the full-length spike of SARS-CoV-2(Ad C68-S).Rapid and high levels of humoral and cellular immune responses were observed after immunization of C57BL/6J mice with one or two doses of Ad ***,neutralizing antibodies were observed up to at least six months after vaccination,without substantial *** or double doses Ad C68-S immunization resulted in lower viral loads in lungs of mice against SARS-CoV-2 challenge both in the short term(21 days)and long-term(6 months).Histopathological examination of Ad C68-S immunized mice lungs showed mild histological abnormalities after SARS-CoV-2 *** together,this study demonstrates the efficacy and durability of the Ad C68-S vaccine and constitutes a promising candidate for clinical evaluation.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分